SCHEMBL429422

SCHEMBL429422

CC(C)(O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.56
KIF11 P52732 1/20 0.52
TNKS O95271 1/20 0.47
PARP1 P09874 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
PTPN5 P54829 1/20 0.47
MMP3 P08254 1/20 0.46
BCL2L1 Q07817 1/20 0.46
ALDH1A1 P00352 2/20 0.45
ESR1 P03372 2/20 0.43
ESR2 Q92731 2/20 0.43
CYP3A4 P08684 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD11B1 P28845 1/20 0.43
CYP17A1 P05093 1/20 0.42
OPRD1 P41143 1/20 0.42
KMT2A Q03164 1/20 0.41
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4506291 1.00 CYP2C9 (0.56) CYP2C9KIF11TNKSPARP1TNKS2
SCHEMBL4517154 0.91 CYP2C9 (0.48) CYP2C9KIF11TNKSPARP1TNKS2
SCHEMBL18802754 0.89 KIF11 (0.44) CYP2C9KIF11TNKSPARP1TNKS2
SCHEMBL547767 0.89 KIF11 (0.44) CYP2C9KIF11TNKSPARP1TNKS2
SCHEMBL4509959 0.89 CYP2C9 (0.45) CYP2C9KIF11TNKSPARP1TNKS2
SCHEMBL18535804 0.85 CYP2C9 (0.56) CYP2C9KIF11PTPN5MMP3BCL2L1
SCHEMBL9279490 0.85 CYP2C9 (0.56) CYP2C9KIF11PTPN5MMP3BCL2L1
SCHEMBL8683368 0.84 ALDH1A1 (0.52) CYP2C9ALDH1A1ESR1ESR2CYP3A4
SCHEMBL164244 0.84 ALDH1A1 (0.52) CYP2C9ALDH1A1ESR1ESR2CYP3A4
SCHEMBL28216352 0.84 ALDH1A1 (0.52) CYP2C9ALDH1A1ESR1ESR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113453724-B Sulfonylmaleimide-based linkers and corresponding conjugates 皮埃尔法布雷医药公司 2025-02-25 CN disclosed
US-11852970-B2 Material for lithography, production method therefor, composition for lithography, pattern formation method, compound, resin, and method for purifying the compound or the resin MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-12-26 US disclosed
US-11572430-B2 Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-02-07 US disclosed
CN-114685243-B Green and efficient preparation method of 2-phenyl-2-propanol series compounds 大连理工大学 2023-02-07 CN disclosed
CN-114685243-A Green and efficient preparation method of 2-phenyl-2-propanol series compounds 大连理工大学 2022-07-01 CN disclosed
CN-110423185-B Method for selectively oxidizing cumene compound 浙江工业大学 2022-03-18 CN disclosed
US-11243467-B2 Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2022-02-08 US disclosed
US-20220023438-A1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES PIERRE FABRE MEDICAMENT (FR) 2022-01-27 US disclosed
EP-3062151-B1 RESIST COMPOSITION, METHOD FOR FORMING RESIST PATTERN, POLYPHENOLIC COMPOUND FOR USE IN THE COMPOSITION, AND ALCOHOLIC COMPOUND THAT CAN BE DERIVED THEREFROM MITSUBISHI GAS CHEMICAL CO (JP) 2021-05-05 EP disclosed
EP-3141957-B1 RESIST MATERIAL, RESIST COMPOSITION, AND RESIST PATTERN FORMATION METHOD MITSUBISHI GAS CHEMICAL CO (JP) 2021-03-24 EP disclosed
US-20070105041-A1 Lithographic printing plate comprising bi-functional compounds AGFA-GEVAERT (BE) 2007-05-10 US disclosed
US-20070105041-A1 Lithographic printing plate comprising bi-functional compounds AGFA-GEVAERT (BE) 2007-05-10 US disclosed
CN-1942825-A Resist composition MITSUBISHI GAS CHEMICAL CO (JP) 2007-04-04 CN disclosed
EP-1739485-A1 RESIST COMPOSITION MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2007-01-03 EP disclosed
US-20030022095-A1 Negative type radiation sensitive resin composition JSR CORPORATION (JP) 2003-01-30 US disclosed
EP-0267759-B1 OXIDATION PROCESS OF AROMATIC COMPOUNDS KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1993-03-10 EP disclosed
US-4825007-A Oxidation process of aromatic compounds KUREHA KAGAKU KOGYO K.K. (JP) 1989-04-25 US disclosed
US-4423038-A Phosphoryl compounds, pharmaceutical preparations containing such compounds, and their use CIBA-GEIGY CORPORATION (US) 1983-12-27 US disclosed
EP-0056992-A1 Phosphorylated derivatives, pharmaceutical compositions containing such derivatives, and their use CIBA-GEIGY AG (CH) 1982-08-04 EP disclosed
US-4159981-A CYCLIC POLYPEPTIDES, DEETHERIFICATION, DEESTERIFICATION CIBA-GEIGY CORPORATION (US) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023438-A1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES CSGALNACT1, CD44, IGLV6-57 CYP2C9 1626/4885KIF11 154/4885TNKS 4022/4885
US-11852970-B2 Material for lithography, production method therefor, composition for lithography, pattern formation method, compound, resin, and method for purifying the compound or the resin SLC39A11, CROCC, TERB1 CYP2C9 2626/4885KIF11 682/4885TNKS 2350/4885
US-11572430-B2 Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method C9, C5, C1R CYP2C9 636/4885KIF11 3842/4885TNKS 2476/4885
US-11243467-B2 Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method C9, C5, C1R CYP2C9 636/4885KIF11 3842/4885TNKS 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.